Sequencing Efficacy Safety Dosing and Administration Expert Conversations Previous Next Read more Previous Play Next GIOTRIF® followed by 3rd generation TKI in UpSwing Sequential Cohort 12/04/2024 | Author: Boehringer Ingelheim Document ID: PC-MY-102189 Sequencing Sequential treatment afatinib RWDRI||Real-World Effectiveness of Sequential GIOTRIF® & osimertinib - Data from GIOTAG and RESET studies SEREAL||GIOTRIF® followed by 3rd generation TKI in GioSwing Sequential Cohort (Combined Analysis of Two Global Non-Interventional Studies) Totality Outcome of Afatinib (GIOTRIF®) Sequential Treatment in Patients with EGFRM+ NSCLC (CNS cohort) GIOTRIF® followed by 3rd generation TKI in UpSwing Sequential Cohort MYSEREAL||GIOTRIF® followed by 3rd generation TKI in RESET study SEREAL||Japan real world evidence supports sequential treatment with the use of upfront 2nd generation TKI SEREAL||GioTag, the 1st global study to show feasibility of sequential therapy with GIOTRIF® followed by osimertinib SEREAL||Post-hoc analyses from LUX-Lung trials: GIOTRIF(R) followed by 3rd generation TKI SEREAL||Uptake of subsequent therapy in LUX-Lung 3, 6 and 7 Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study Totality Outcome of Afatinib (GIOTRIF®) Sequential Treatment in Patients with EGFRM+ NSCLC RELATED CONTENT Read more PDF GioTag, the 1st global study to show feasibility of sequential therapy with GIOTRIF® followed by osimertinib Download Opens in new tab Read more PDF Post-hoc analyses from LUX-Lung trials: GIOTRIF(R) followed by 3rd generation TKI Download Opens in new tab Read more PDF Uptake of subsequent therapy in LUX-Lung 3, 6 and 7 Download Opens in new tab Read more PDF Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study Download Opens in new tab Read more PDF Totality Outcome of Afatinib (GIOTRIF®) Sequential Treatment in Patients with EGFRM+ NSCLC Download Opens in new tab Home Oncology Giotrif Sequencing GIOTRIF® followed by 3rd generation TKI in UpSwing Sequential Cohort
Read more PDF GioTag, the 1st global study to show feasibility of sequential therapy with GIOTRIF® followed by osimertinib Download Opens in new tab
Read more PDF Post-hoc analyses from LUX-Lung trials: GIOTRIF(R) followed by 3rd generation TKI Download Opens in new tab
Read more PDF Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study Download Opens in new tab
Read more PDF Totality Outcome of Afatinib (GIOTRIF®) Sequential Treatment in Patients with EGFRM+ NSCLC Download Opens in new tab